{"id":525,"date":"2026-08-09T19:52:52","date_gmt":"2026-08-09T19:52:52","guid":{"rendered":"https:\/\/newt-peptide.local\/peptide-dosages\/retatrutide-dosage-reference\/"},"modified":"2026-08-09T19:52:52","modified_gmt":"2026-08-09T19:52:52","slug":"retatrutide-dosage-reference","status":"publish","type":"newt_dosage","link":"https:\/\/newtpeptide.com\/peptide-dosages\/retatrutide-dosage-reference\/","title":{"rendered":"Retatrutide"},"content":{"rendered":"<p>A single Retatrutide research-reference page shared by every available product strength.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Retatrutide peptide is an investigational incretin-based metabolic drug being studied for obesity, type 2 diabetes, and related cardiometabolic conditions. Retatrutide, also known as LY3437943, is a peptide-class triple agonist that activates the GIP, GLP-1, and glucagon receptors<\/p>\n","protected":false},"template":"","meta":{"footnotes":""},"class_list":["post-525","newt_dosage","type-newt_dosage","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/newtpeptide.com\/wp-json\/wp\/v2\/newt_dosage\/525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newtpeptide.com\/wp-json\/wp\/v2\/newt_dosage"}],"about":[{"href":"https:\/\/newtpeptide.com\/wp-json\/wp\/v2\/types\/newt_dosage"}],"version-history":[{"count":1,"href":"https:\/\/newtpeptide.com\/wp-json\/wp\/v2\/newt_dosage\/525\/revisions"}],"predecessor-version":[{"id":526,"href":"https:\/\/newtpeptide.com\/wp-json\/wp\/v2\/newt_dosage\/525\/revisions\/526"}],"wp:attachment":[{"href":"https:\/\/newtpeptide.com\/wp-json\/wp\/v2\/media?parent=525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}